Background: Behavior change interventions that aim to improve rational antibiotic use in prescribers and users have been widely conducted in both high- and LMICs. However, currently, no review has systematically examined challenges unique to LMICs and offered insights into the underlying contextual factors that influence these interventions. We adopted an implementation research perspective to systematically synthesize the implementation barriers and facilitators in LMICs. Methods: We conducted literature searches in five electronic databases and identified studies that involved the implementation of behavior change interventions to improve appropriate antibiotic use in prescribers and users in LMICs and reported implementation barriers and facilitators. Behavior change interventions were defined using the behavior change wheel, and the coding and synthesis of barriers and facilitators were guided by the Consolidated Framework for Implementation Research (CFIR). Results: We identified 52 eligible studies, with the majority targeting prescribers practicing at tertiary facilities (N=39, 75%). The most commonly reported factors influencing implementation were found in the inner setting domain of the CFIR framework, particularly related to constraints in resources and the infrastructure of the facilities where interventions were implemented. Barriers related to the external policy environment (e.g., lack of national initiatives and policies on antibiotic use), and individual characteristics of target populations (e.g., reluctance to change prescribing behaviors) were also common, as well as facilitators related to intervention characteristics (e.g., embedding interventions in routine practice) and process (e.g., stakeholder engagement). We also provided insights into the interrelationships between these factors and the underlying causes contributing to the implementation challenges in LMICs. Conclusion: We presented a comprehensive overview of the barriers and facilitators of implementing behavior change interventions to promote rational antibiotic use in LMICs. Our findings suggest that facilitating the implementation of interventions to improve rational antibiotic use needs comprehensive efforts to address challenges at policy, organizational, and implementation levels. Specific strategies include (1) strengthening political commitment to prompt mobilization of domestic resources and formulation of a sustainable national strategy on AMR, (2) improving the infrastructure of health facilities that allow prescribers to make evidence-based clinical decisions, and (3) engaging local stakeholders to improve their buy-in and facilitate contextualizing interventions. Trial registration: PROSPERO: CRD42021252715.
Direct Oral Anti-Coagulants (DOACs) are the primary treatment for the long-term prevention of stroke in patients with atrial fibrillation. Strict adherence to DOAC therapy is crucial and must be maintained over the long term. Therefore, predicting long-term adherence is valuable for identifying patients at risk of non-adherence. We developed a novel method for predicting long-term adherence using first-order Markov models to assess adherence in new DOAC users during years 2–5. The prediction utilized age, CHA2DS2-VASc score, and first-year adherence data as predictors. Adherence was measured by calculating the proportion of days covered within consecutive 90-day windows, which were then stratified into deciles. We subsequently calculated the probability of a patient being in a specific adherence decile. The developed model demonstrated good calibration. We discovered that missing even 1 day of treatment per month in the first year was predictive of a lower likelihood of achieving the highest adherence decile in years 2–5. Additionally, we noted a non-linear relationship between age and adherence; adherence increased linearly with age but plateaued around age 75. This innovative approach to modelling and predicting adherence to DOACs for long-term therapy can help identify patients at risk of low adherence and may be applicable to other chronic medications.